Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Malignant Pleural Mesothelioma. According to GlobalData, Phase II drugs for Malignant Pleural Mesothelioma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Alintegimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Alintegimod overview
7HP-349 is under development for the treatment of metastatic melanoma, hematopoietic stem cell transplantation, influenza, melanoma, pleural mesothelioma, renal cell carcinoma, MSI-high or mismatch repair-deficient colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer and solid tumors. It is administered through oral route. The drug candidate is a softgel capsule, which acts as activators of VLA-4 and LFA-1 cell adhesion axes. The drug candidate acts by targeting integrin.
7 Hills Pharma overview
7 Hills Pharma is a clinical stage pharmaceutical company, that develops first-in-concept integrin activators to augment immunotherapies for the treatment of drug resistant solid tumors and infectious diseases. 7 Hills Pharma is headquartered in Houston, Texas, the US.
For a complete picture of Alintegimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
